CN1440462A - 鉴定和生产抗原肽的方法并且将其用作疫苗 - Google Patents

鉴定和生产抗原肽的方法并且将其用作疫苗 Download PDF

Info

Publication number
CN1440462A
CN1440462A CN01812119A CN01812119A CN1440462A CN 1440462 A CN1440462 A CN 1440462A CN 01812119 A CN01812119 A CN 01812119A CN 01812119 A CN01812119 A CN 01812119A CN 1440462 A CN1440462 A CN 1440462A
Authority
CN
China
Prior art keywords
epi
virus
cell
vaccine
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01812119A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·J·L·西马德
戴维·C·戴蒙德
雷向东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/561,074 external-priority patent/US6861234B1/en
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of CN1440462A publication Critical patent/CN1440462A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
CN01812119A 2000-04-28 2001-04-27 鉴定和生产抗原肽的方法并且将其用作疫苗 Pending CN1440462A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US56157200A 2000-04-28 2000-04-28
US56157100A 2000-04-28 2000-04-28
US56046500A 2000-04-28 2000-04-28
US09/561,074 2000-04-28
US09/561,074 US6861234B1 (en) 2000-04-28 2000-04-28 Method of epitope discovery
US09/561,572 2000-04-28
US09/561,571 2000-04-28
US09/560,465 2000-04-28

Publications (1)

Publication Number Publication Date
CN1440462A true CN1440462A (zh) 2003-09-03

Family

ID=27504814

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01812119A Pending CN1440462A (zh) 2000-04-28 2001-04-27 鉴定和生产抗原肽的方法并且将其用作疫苗

Country Status (12)

Country Link
US (1) US20070269464A1 (https=)
EP (4) EP1276896B1 (https=)
JP (1) JP2003535824A (https=)
CN (1) CN1440462A (https=)
AT (1) ATE474931T1 (https=)
AU (3) AU5741001A (https=)
CA (1) CA2405363A1 (https=)
DE (1) DE60142615D1 (https=)
DK (1) DK1276896T3 (https=)
ES (1) ES2347762T3 (https=)
NZ (1) NZ521715A (https=)
WO (1) WO2001082963A2 (https=)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101246176B (zh) * 2007-02-13 2013-06-05 许洋 鳞状细胞癌抗原阴性宫颈癌血清蛋白质检测的质谱试剂及其制备方法
CN104761644A (zh) * 2014-01-03 2015-07-08 百奇生物科技（苏州）有限公司 大肠杆菌表达的融合蛋白mbp-mart-1及其制备和应用
CN105067731A (zh) * 2015-06-05 2015-11-18 中国农业科学院兰州兽医研究所 一种弓形虫感染后血清中生物标记物的筛选方法及筛选出的生物标记物的应用
CN105175498A (zh) * 2015-10-09 2015-12-23 深圳市康尔诺生物技术有限公司 一种宫颈癌相关的热休克蛋白复合物及其应用
CN105682679A (zh) * 2013-11-01 2016-06-15 辉瑞公司 用于表达前列腺相关抗原的载体
CN108603171A (zh) * 2015-12-23 2018-09-28 基因医疗免疫疗法有限责任公司 新一代抗原-特异性tcr
CN110187122A (zh) * 2012-09-05 2019-08-30 亚利桑那州评议委员会,亚利桑那州法人团体,代理和代表亚利桑那州立大学 发现治疗靶标的方法
CN110291402A (zh) * 2016-06-27 2019-09-27 朱诺治疗学股份有限公司 鉴定肽表位的方法、结合此类表位的分子和相关用途
CN110809580A (zh) * 2017-01-24 2020-02-18 安贝科思生物制剂公司 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物
CN111529697A (zh) * 2011-05-26 2020-08-14 金纽斯生物科技投资有限责任公司 调节的免疫优势疗法
CN113484523A (zh) * 2015-02-12 2021-10-08 生物技术Rna制药有限公司 预测可用于疫苗接种的t细胞表位
CN113549153A (zh) * 2014-05-29 2021-10-26 宏观基因有限公司 三特异性结合分子和其使用方法
CN114729361A (zh) * 2019-11-15 2022-07-08 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
CN115916248A (zh) * 2020-03-03 2023-04-04 穆罕默德·塔雷克 Custommune：设计个性化和群体靶向肽疫苗的网络工具
US12270813B2 (en) 2017-06-09 2025-04-08 BioNTech SE Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6773695B2 (en) * 2000-10-05 2004-08-10 Mannkind Corporation Modulation of allergic response
JP2005505242A (ja) * 2001-03-07 2005-02-24 マンカインド コーポレイション 癌用抗新生血管系調製物
EP1595548A3 (en) * 2001-03-07 2006-02-22 Mannkind Corporation Anti-neovasculature preparations for treating cancer
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP1752160A3 (en) 2001-04-06 2007-05-30 Mannkind Corporation Epitope sequences
US8637305B2 (en) 2001-11-07 2014-01-28 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
AU2008229888B2 (en) * 2001-11-07 2012-07-05 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
WO2004022709A2 (en) * 2002-09-06 2004-03-18 Mannkind Corporation Epitope sequences
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
CN102370974B (zh) 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
DE602004031116D1 (de) 2003-07-22 2011-03-03 Ludwig Inst For Cancer Res New York Von hla-klasse-ii-molekülen präsentierte ssx-2-peptide
AU2005321898B2 (en) * 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
EP1838342A2 (en) * 2004-12-29 2007-10-03 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
MX2007015933A (es) * 2005-06-17 2008-04-21 Mannkind Corp Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales.
CN101687020A (zh) * 2005-06-17 2010-03-31 曼康公司 用于癌症的多价引发-和-增强免疫治疗剂
ES2579762T3 (es) * 2006-03-01 2016-08-16 Janssen Pharmaceutica N.V. Tratamiento del cáncer combinando agente linfo - reductor con CLTs y citoquinas
WO2007109321A2 (en) 2006-03-20 2007-09-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
WO2008008541A2 (en) * 2006-07-14 2008-01-17 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
CA2665816C (en) 2006-09-21 2016-07-12 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
EP2398504B1 (en) 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
CA2782333C (en) 2009-12-02 2019-06-04 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
WO2012031076A1 (en) * 2010-09-02 2012-03-08 Ludwig Institute For Cancer Research, Ltd. Recombinant trypanosoma cruzi cells useful as anti-cancer immune agents
AU2014228405B2 (en) * 2013-03-15 2017-05-11 The Trustees Of The University Of Pennsylvania Cancer vaccines and methods of treatment using the same
CN103837688A (zh) * 2014-03-27 2014-06-04 吉林农业大学 一种检测犬猫弓形虫抗体的间接elisa试剂盒
DK3122375T3 (da) 2014-03-28 2021-05-25 Univ Washington Through Its Center For Commercialization Vacciner mod bryst- og ovariecancer
WO2015149010A1 (en) * 2014-03-28 2015-10-01 University Of Washington Through Its Center For Commercialization Methods of identifying antigens for vaccines
US9549914B2 (en) 2014-04-03 2017-01-24 The Johns Hopkins University Treatment of human cytomegalovirus by modulating Wnt
CN104142401B (zh) * 2014-07-25 2016-04-20 北京普恩光德生物科技开发有限公司 膀胱肿瘤相关抗原检测试剂盒
WO2017027325A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
WO2017096247A1 (en) 2015-12-04 2017-06-08 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different mhc molecules
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
WO2018217852A1 (en) * 2017-05-23 2018-11-29 Gettysburg College Crispr based tool for characterizing bacterial serovar diversity
WO2024050547A2 (en) * 2022-09-02 2024-03-07 Hunterian Medicine Llc Compact bidirectional promoters for gene expression

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439199A (en) * 1980-02-19 1984-03-27 Alza Corporation Method for administering immunopotentiator
US4683199A (en) * 1983-01-31 1987-07-28 Sloan-Kettering Institute For Cancer Research Interleukin-2 dependent cytotoxic T-cell clones
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5093242A (en) * 1986-10-02 1992-03-03 Massachusetts Institute Of Technology Methods of generating desired amino-terminal residues in proteins
US5196321A (en) * 1986-10-02 1993-03-23 Massachusetts Institute Of Technology Methods for in vitro cleavage of ubiquitin fusion proteins
US5132213A (en) * 1986-10-02 1992-07-21 Massachusetts Institute Of Technology Method for producing proteins and polypeptides using ubiquitin fusions
US4937190A (en) * 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
NZ227934A (en) * 1988-02-12 1991-06-25 Commw Scient Ind Res Org Fowlpox virus vectors
US6723832B1 (en) * 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1991006866A2 (en) 1989-11-03 1991-05-16 Morton Donald L Urinary tumor associated antigen, antigenic subunits uses and methods of detection
DE4143467C2 (de) * 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5744316A (en) * 1992-12-22 1998-04-28 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
US5989565A (en) 1993-01-29 1999-11-23 University Of Pittsburgh Elution and identification of T cell epitopes from viable cells
EP0689551B1 (en) * 1993-03-17 2008-02-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5478556A (en) * 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
DE4423392A1 (de) * 1994-07-04 1996-01-11 Birsner & Grob Biotech Gmbh Verfahren zur Identifizierung antigener Peptide
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
JP4108126B2 (ja) * 1996-04-26 2008-06-25 リュクスウニヴェルシテート テ レイデン Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
CN1100673C (zh) 1997-07-03 2003-02-05 松下电器产业株式会社 喷墨打印头及其制造方法
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
EP1118860A1 (en) * 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US20040236514A1 (en) * 2001-12-13 2004-11-25 Lee Stephen C. Controlling distribution of epitopes in polypeptide sequences

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101246176B (zh) * 2007-02-13 2013-06-05 许洋 鳞状细胞癌抗原阴性宫颈癌血清蛋白质检测的质谱试剂及其制备方法
CN111529697A (zh) * 2011-05-26 2020-08-14 金纽斯生物科技投资有限责任公司 调节的免疫优势疗法
CN110187122A (zh) * 2012-09-05 2019-08-30 亚利桑那州评议委员会,亚利桑那州法人团体,代理和代表亚利桑那州立大学 发现治疗靶标的方法
CN105682679B (zh) * 2013-11-01 2020-12-08 辉瑞公司 用于表达前列腺相关抗原的载体
CN105682679A (zh) * 2013-11-01 2016-06-15 辉瑞公司 用于表达前列腺相关抗原的载体
CN104761644A (zh) * 2014-01-03 2015-07-08 百奇生物科技（苏州）有限公司 大肠杆菌表达的融合蛋白mbp-mart-1及其制备和应用
CN113549153A (zh) * 2014-05-29 2021-10-26 宏观基因有限公司 三特异性结合分子和其使用方法
CN113484523A (zh) * 2015-02-12 2021-10-08 生物技术Rna制药有限公司 预测可用于疫苗接种的t细胞表位
CN105067731A (zh) * 2015-06-05 2015-11-18 中国农业科学院兰州兽医研究所 一种弓形虫感染后血清中生物标记物的筛选方法及筛选出的生物标记物的应用
CN105175498A (zh) * 2015-10-09 2015-12-23 深圳市康尔诺生物技术有限公司 一种宫颈癌相关的热休克蛋白复合物及其应用
CN108603171A (zh) * 2015-12-23 2018-09-28 基因医疗免疫疗法有限责任公司 新一代抗原-特异性tcr
CN110291402A (zh) * 2016-06-27 2019-09-27 朱诺治疗学股份有限公司 鉴定肽表位的方法、结合此类表位的分子和相关用途
CN110291402B (zh) * 2016-06-27 2023-09-01 朱诺治疗学股份有限公司 鉴定肽表位的方法、结合此类表位的分子和相关用途
CN110809580A (zh) * 2017-01-24 2020-02-18 安贝科思生物制剂公司 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物
US12270813B2 (en) 2017-06-09 2025-04-08 BioNTech SE Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
CN114729361A (zh) * 2019-11-15 2022-07-08 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
CN114729361B (zh) * 2019-11-15 2024-05-03 上海细胞治疗集团股份有限公司 一种在活化的t细胞中具有高活性的启动子
CN115916248A (zh) * 2020-03-03 2023-04-04 穆罕默德·塔雷克 Custommune：设计个性化和群体靶向肽疫苗的网络工具

Also Published As

Publication number Publication date
US20070269464A1 (en) 2007-11-22
DE60142615D1 (de) 2010-09-02
NZ521715A (en) 2008-01-31
EP1276896B1 (en) 2010-07-21
WO2001082963A3 (en) 2002-04-11
WO2001082963A2 (en) 2001-11-08
CA2405363A1 (en) 2001-11-08
AU2001257410B2 (en) 2006-08-24
DK1276896T3 (da) 2010-10-18
EP2278023A1 (en) 2011-01-26
HK1053333A1 (en) 2003-10-17
AU2010251790A1 (en) 2011-01-06
ES2347762T3 (es) 2010-11-04
EP2278024A1 (en) 2011-01-26
EP1276896A2 (en) 2003-01-22
ATE474931T1 (de) 2010-08-15
AU2001257410B8 (en) 2006-12-21
EP2248910A1 (en) 2010-11-10
JP2003535824A (ja) 2003-12-02
AU2010251790B2 (en) 2013-02-07
AU5741001A (en) 2001-11-12
AU2001257410B9 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
CN1440462A (zh) 鉴定和生产抗原肽的方法并且将其用作疫苗
US6861234B1 (en) Method of epitope discovery
US20030215425A1 (en) Epitope synchronization in antigen presenting cells
AU2001257410A1 (en) Method of identifying and producing antigen peptides and use thereof as vaccines
CN1791433A (zh) 抗肿瘤生长的dna疫苗及其使用方法
CN1805758A (zh) 核酸和细胞疫苗的组分
CN1675237A (zh) 免疫原性组合物
CN1646153A (zh) 抗血管生成的主动免疫疗法
CN1196495C (zh) 突变的人cd80及其制备和应用组合物和方法
CN100347191C (zh) 新mhcⅱ相关肽
CN1738834A (zh) Hcv 疫苗
CN1281748C (zh) 为改善IL－12活性而突变的IL－12p40亚基基因及其作为DNA疫苗佐剂的用途
CN1548537A (zh) 疫苗制备方法和抗肿瘤疫苗
JP2009279006A (ja) 抗原提示細胞におけるエピトープ同調
CN1280307C (zh) 细胞毒性t淋巴细胞
CN101048178A (zh) 作为疫苗的重组分枝杆菌和生物活性剂的组合
CN1720261A (zh) 疫苗
CN1948333A (zh) 一种新的hPEBP4蛋白来源的HLA－A2限制性表位多肽及其应用
CN1370231A (zh) Casb618多核苷酸和多肽及其用途
CN1262562C (zh) 来源于sart－1的hla－a2限制性肿瘤抗原肽
CN1289146C (zh) 一种新型预防和治疗乙肝病毒感染的核酸疫苗及制备方法
CN1305384A (zh) Mmtv抗原的免疫调节组合物及其使用方法
CN1976946A (zh) 诱导抗hcv有效ctl应答的超型表位、其编码寡核苷酸及其应用
CN1737147A (zh) 热休克蛋白65－多表位乙型肝炎病毒核心抗原重组融合蛋白（HSP65－HBcAg）
AU2006246500B2 (en) Epitope synchronization in antigen presenting cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20030903